Members

  First name: Charlotte
  Last name: Charpentier
  Function: Medical biologist, researcher
  Position: Associate professor
  Email: charlotte.charpentier
._
_.
inserm.fr

Research interest


My main research interest is HIV-1 resistance to antiretroviral drugs. I especially worked on the role of minority resistant variants on the development of resistance. I’m on the board of the French ANRS (National Agency for AIDS Research) AC11 Resistance group providing HIV-1 and HIV-2 genotypic drug resistance interpretation’s algorithms in order to guide physicians in the choice of antiretroviral treatment. I am also deeply involved in studying the pathophysiology of HIV-2 infection and HIV-2 resistance to ARV. Indeed, the laboratory is the virological coordinator of the cohort ANRS HIV-2 with over 1 000 patients included, the larger HIV-2 cohort in Northern countries.

Education

Degree

2005: Ph.D. in Biochemistry and Molecular Biology, option Virology, University Paris 6
2003: Pharm. D., University Paris Descartes
1993-1998: Second cycle of pharmaceutical studies, University Paris Descartes

Academic positions

2012-present: Associate Professor in Virology, Medical School, Paris Diderot University
2005-2009: Assistant Professor in Virology, Hôpital Européen Georges Pompidou, Medical School, University Paris Descartes
1999-2003: Resident, Assistance Publique-Hôpitaux de Paris

List of the main publications

Charpentier C, Camacho R, Ruelle J, Eberle J, Gürtler L, Pironti A, Stürmer M, Brun-Vézinet F, Kaiser R, Descamps D, Obermeier M
HIV-2EU-Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2015, 61, 1346–1347.

Charpentier C, Lee GQ, Rodriguez C, Visseaux B, Storto A, Fagard C, Molina JM, Katlama C, Yazdanpanah Y, Harrigan PR, Descamps D
Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
The Journal of Antimicrobial Chemotherapy 2015, 70, 2090-2096.

Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D, ACH2C
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
AIDS (London, England) 2015, 29, 779–784.

Charpentier C, Camacho R, Ruelle J, Kaiser R, Eberle J, Gürtler L, Pironti A, Stürmer M, Brun-Vézinet F, Descamps D, Obermeier M
HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2013, 56, 1654-1658.

Charpentier C, Bertine M, Visseaux B, Leleu J, Larrouy L, Peytavin G, Mourez T, Collin G, Brun-Vézinet F, Plantier JC, Descamps D
In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.
AIDS (London, England) 2013, 27, 2959-2961.


Exhaustive list of publications

2022


Ferré VM, Peiffer-Smadja N, Visseaux B, Descamps D, Ghosn J, Charpentier C
Omicron SARS-CoV-2 variant: What we know and what we don't.
Anaesthesia, Critical Care & Pain Medicine 2022, 41, 100998.

Lebourgeois S, Menidjel R, Chenane HR, Ferré VM, Collin G, Damond F, Coppée R, Yazdanpanah Y, Timsit JF, Houhou-Fidouh N, Descamps D, Charpentier C, Visseaux B
Alpha (B.1.1.7) and Delta (B.1.617.2 - AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage.
The Journal of Infection 2022, 84, 418-467.

Ferré VM, Lebourgeois S, Chenane HR, Menidjel R, Masson C, Collin G, Visseaux B, Descamps D, Fidouh N, Charpentier C
Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays.
The Journal of Infection 2022, S0163-4453(22)00126-8.

Gounant V, Ferré VM, Soussi G, Charpentier C, Flament H, Fidouh N, Collin G, Namour C, Assoun S, Bizot A, Brouk Z, Vicaut E, Teixeira L, Descamps D, Zalcman G
Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses.
Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2022, 17, 239-251.

Wurtzer S, Waldman P, Levert M, Cluzel N, Almayrac JL, Charpentier C, Masnada S, Gillon-Ritz M, Mouchel JM, Maday Y, Boni M, OC, AHVG, Marechal V, Moulin L
SARS-CoV-2 genome quantification in wastewaters at regional and city scale allows precise monitoring of the whole outbreaks dynamics and variants spreading in the population.
The Science of the Total Environment 2022, 810, 152213.

Le Hingrat Q, Collin G, Damond F, Peytavin G, Lebourgeois S, Ghosn J, Bachelard A, Ferré VM, Matheron S, Descamps D, Charpentier C
In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions.
The Journal of Antimicrobial Chemotherapy 2022, 77, 409-412.

Le Hingrat Q, Collin G, Bachelard A, Ghosn J, Chalal S, Pacanowski J, Peytavin G, Weinheimer S, Marsolais C, Damond F, Matheron S, Charpentier C, Descamps D, atACH2c
Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates.
AIDS (London, England) 2022

Mageau A, Ferré VM, Goulenok T, Charpentier C, Delory N, Francois C, Houhou-Fidouh N, Papo T, Descamps D, Sacre K
Severely impaired humoral response against SARS-CoV-2 variants of concern following two doses of BNT162b2 vaccine in patients with systemic lupus erythematosus (SLE).
Annals of the Rheumatic Diseases 2022, annrheumdis-2022-222498.

Contejean A, Abbara S, Chentouh R, Alviset S, Grignano E, Gastli N, Casetta A, Willems L, Canouï E, Charlier C, Pène F, Charpentier J, Reboul-Marty J, Batista R, Bouscary D, Kernéis S
Antimicrobial stewardship in high-risk febrile neutropenia patients.
Antimicrobial Resistance and Infection Control 2022, 11, 52.

2021


Vauloup-Fellous C, Maylin S, Périllaud-Dubois C, Brichler S, Alloui C, Gordien E, Rameix-Welti MA, Gault E, Moreau F, Fourati S, Challine D, Pawlotsky JM, Houhou-Fidouh N, Damond F, Mackiewicz V, Charpentier C, Méritet JF, Rozenberg F, Podglajen I, Marot S, Petit H, Burrel S, Akhavan S, Leruez-Ville M, Avettand-Fenoel V, Fourgeaud J, Guilleminot T, Gardiennet E, Bonacorsi S, Carol A, Carcelain G, Villemonteix J, Boukli N, Gozlan J, Morand-Joubert L, Legoff J, Delaugerre C, Chaix ML, Roque-Afonso AM, Dortet L, Naas T, Ronat JB, Lepape S, Marcelin AG, Descamps D
Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients.
European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 2021, 40, 2235-2241.

Husain M, Rachline A, Cousien A, Rolland S, Rouzaud C, Ferre VM, Gomez MV, Le Teurnier M, Wicky-Thisse M, Descamps D, Yazdanpanah Y, Charpentier C, Pasquet-Cadre A
Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March-May 2020).
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2021, 27, 1520.e1-1520.e5.

Charpentier C, Pellissier G, Ichou H, Ferré VM, Larfi I, Phung BC, Vallois D, LeGac S, Aubier M, Descamps D, Fidouh-Houhou N, Bouvet E
Contribution of rapid lateral flow assays from capillary blood specimens to the diagnosis of COVID-19 in symptomatic healthcare workers: a pilot study in a university hospital, Paris, France.
Diagnostic Microbiology and Infectious Disease 2021, 101, 115430.

Tubiana S, Burdet C, Houhou N, Thy M, Manchon P, Blanquart F, Charpentier C, Guedj J, Alavoine L, Behillil S, Leclercq A, Lucet JC, Yazdanpanah Y, Attia M, Demeret C, Rose T, Bielicki JA, Bruijning-Verhagen P, Goossens H, Descamps D, van der Werf S, Lina B, Duval X
High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort.
The Journal of Infection 2021, 82, 186-230.

Teyssou E, Soulie C, Visseaux B, Lambert-Niclot S, Ferre V, Marot S, Jary A, Sayon S, Zafilaza K, Leducq V, Schnuriger A, Abdi B, Wirden M, Houhou-Fidouh N, Charpentier C, Morand-Joubert L, Burrel S, Descamps D, Calvez V, Marcelin AG
The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients.
The Journal of Infection 2021, 83, 119-145.

Teyssou E, Delagrèverie H, Visseaux B, Lambert-Niclot S, Brichler S, Ferre V, Marot S, Jary A, Todesco E, Schnuriger A, Ghidaoui E, Abdi B, Akhavan S, Houhou-Fidouh N, Charpentier C, Morand-Joubert L, Boutolleau D, Descamps D, Calvez V, Marcelin A, Soulie C
The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19.
The Journal of Infection 2021, S0163-4453(21)00416-3.

Ferré VM, Lebourgeois S, Menidjel R, Collin G, Chenane HR, Guindi MO, Yazdanpanah Y, Timsit JF, Charpentier C, Descamps D, Fidouh N, Visseaux B
Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine.
The Journal of Infection 2021, S0163-4453(21)00488-6.

Visseaux B, Collin G, Houhou-Fidouh N, Le Hingrat Q, Ferré VM, Damond F, Ichou H, Descamps D, Charpentier C
Evaluation of three extraction-free SARS-CoV-2 RT-PCR assays: A feasible alternative approach with low technical requirements.
Journal of Virological Methods 2021, 291, 114086.

Diallo MS, Samri A, Charpentier C, Bertine M, Cheynier R, Thiébaut R, Matheron S, Collin F, Braibant M, Candotti D, Brun-Vézinet F, Autran B, ACI2aACASG
A Comparison of Cell Activation, Exhaustion, and Expression of HIV Coreceptors and Restriction Factors in HIV-1- and HIV-2-Infected Nonprogressors.
AIDS research and human retroviruses 2021, 37, 214-223.

Berzow D, Descamps D, Obermeier M, Charpentier C, Kaiser R, Guertler L, Eberle J, Wensing A, Sierra S, Ruelle J, Gomes P, Mansinho K, Taylor N, Jensen B, Döring M, Stürmer M, Rockstroh J, Camacho R
Human Immunodeficiency Virus-2 (HIV-2): A Summary of the Present Standard of Care and Treatment Options for Individuals Living with HIV-2 in Western Europe.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2021, 72, 503-509.

Charpentier C, Storto A, Soulié C, Ferré VM, Wirden M, Joly V, Lambert-Niclot S, Palich R, Morand-Joubert L, Landman R, Lacombe K, Katlama C, Ghosn J, Marcelin AG, Calvez V, Descamps D
Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.
The Journal of Antimicrobial Chemotherapy 2021

Charpentier C, Storto A, Soulié C, Ferré VM, Wirden M, Joly V, Lambert-Niclot S, Palich R, Morand-Joubert L, Landman R, Lacombe K, Katlama C, Ghosn J, Marcelin AG, Calvez V, Descamps D
Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.
The Journal of Antimicrobial Chemotherapy 2021, 76, 2983-2987.

Marcelin AG, Charpentier C, Bellecave P, Abdi B, Chaix ML, Ferre V, Raymond S, Fofana D, Bocket L, Mirand A, Le Guillou-Guillemette H, Montes B, Amiel C, Pallier C, Fafi-Kremer S, De Monte A, Alessandri-Gradt E, Scholtes C, Maillard A, Jeulin H, Bouvier-Alias M, Roussel C, Dos Santos G, Signori-Schmuck A, Dina J, Vallet S, Stefic K, Soulié C, Calvez V, Descamps D, Flandre P, AMAG
Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.
The Journal of Antimicrobial Chemotherapy 2021, 76, 2400-2406.

Martin C, Gracias S, Charpentier C, Descamps D, Le Hingrat Q, Plantier JC, Alessandri-Gradt E
HIV-1 non-group M phenotypic susceptibility in vitro to bictegravir and cabotegravir.
The Journal of Antimicrobial Chemotherapy 2021, 76, 2306-2309.

Visseaux B, Bertine M, Le Hingrat Q, Ferré V, Charpentier C, Collin F, Damond F, Matheron S, Hué S, Descamps D
HIV-2 diversity displays two clades within group A with distinct geographical distribution and evolution.
Virus Evolution 2021, 7, veab024.

Tchankoni MK, Bitty-Anderson AM, Sadio AJ, Gbeasor-Komlanvi FA, Ferré VM, Zida-Compaore WIC, Dorkenoo AM, Saka B, Dagnra AC, Charpentier C, Ekouevi DK
Prevalence and factors associated with trichomonas vaginalis infection among female sex workers in Togo, 2017.
BMC infectious diseases 2021, 21, 775.

Bitty-Anderson AM, Ferré V, Gbeasor-Komlanvi FA, Tchankoni MK, Sadio A, Salou M, Descamps D, Dagnra CA, Charpentier C, Ekouevi DK, Coffie PA
Prevalence of hepatitis B and C among female sex workers in Togo, West Africa.
PloS One 2021, 16, e0259891.

Lebourgeois S, Chenane HR, Houhou-Fidouh N, Menidjel R, Ferré VM, Collin G, Benmalek N, Coppée R, Larrouy L, Yazdanpanah Y, Timsit JF, Charpentier C, Descamps D, Visseaux B
Earlier In Vitro Viral Production With SARS-CoV-2 Alpha Than With Beta, Gamma, B, or A.27 Variants.
Frontiers in Cellular and Infection Microbiology 2021, 11, 792202.

Peiffer-Smadja N, Bridier-Nahmias A, Ferré VM, Charpentier C, Garé M, Rioux C, Allemand A, Lavallée P, Ghosn J, Kramer L, Descamps D, Yazdanpanah Y, Visseaux B
Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2.
Viruses 2021, 13, 1642.

2020


Hingrat QL, Visseaux B, Laouenan C, Tubiana S, Bouadma L, Yazdanpanah Y, Duval X, Burdet C, Ichou H, Damond F, Bertine M, Benmalek N, Choquet C, Timsit JF, Ghosn J, Charpentier C, Descamps D, Houhou-Fidouh N, FCcmcCCsg, motFCcsg(ao, motCCsgPi, SC, CCCC, Casa, VL, BC, P, S, G
Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2020, S1198-743X(20)30721-7.

André-Garnier E, Hingrat QL, Marcelin AG, Reliquet V, Malet I, Leducq V, Rodallec A, Peytavin G, Ferré V, Charpentier C, Raffi F
Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.
International Journal of Antimicrobial Agents 2020, 106039.

Battesti G, El Khalifa J, Abdelhedi N, Ferre V, Bouscarat F, Picard-Dahan C, Brunet-Possenti F, Collin G, Lavaud J, Le Bozec P, Rousselot M, Tournier A, Lheure C, Couvelard A, Hacein-Bey-Abina S, Abina AM, Charpentier C, Mignot S, Nicaise P, Descamps D, Deschamps L, Descamps V
New insights in COVID-19–associated chilblains: A comparative study with chilblain lupus erythematosus.
Journal of the American Academy of Dermatology 2020, 83, 1219-1222.

Charpentier C, Ichou H, Damond F, Bouvet E, Chaix ML, Ferré V, Delaugerre C, Mahjoub N, Larrouy L, Le Hingrat Q, Visseaux B, Mackiewicz V, Descamps D, Fidouh-Houhou N
Performance evaluation of two SARS-CoV-2 IgG/IgM rapid tests (Covid-Presto and NG-Test) and one IgG automated immunoassay (Abbott).
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2020, 132, 104618.

Tzou PL, Descamps D, Rhee SY, Raugi DN, Charpentier C, Taveira N, Smith RA, Soriano V, de Mendoza C, Holmes SP, Gottlieb GS, Shafer RW
Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.
The Journal of Infectious Diseases 2020, 221, 1962-1972.

Jary A, Marcelin AG, Charpentier C, Wirden M, Lê MP, Peytavin G, Descamps D, Calvez V
M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.
The Journal of Antimicrobial Chemotherapy 2020, 75, 1290-1293.

Charpentier C, Peytavin G, Raffi F, Burdet C, Landman R, Lê MP, Katlama C, Collin G, Benalycherif A, Cabie A, Mentré F, Yazdanpanah Y, Descamps D, Joly V
Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).
The Journal of Antimicrobial Chemotherapy 2020, 75, 1611-1617.

Marcelin AG, Charpentier C, Jary A, Perrier M, Margot N, Callebaut C, Calvez V, Descamps D
Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients.
The Journal of Antimicrobial Chemotherapy 2020, 75, 1588-1590.

Soulie C, Santoro MM, Storto A, Abdi B, Charpentier C, Armenia D, Jary A, Forbici F, Bertoli A, Gennari W, Andreoni M, Mussini C, Antinori A, Perno CF, Calvez V, Ceccherini-Silberstein F, Descamps D, Marcelin AG
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
The Journal of Antimicrobial Chemotherapy 2020, 75, 1026-1030.

Mossoro-Kpinde CD, Gody JC, Mboumba Bouassa RS, Moussa S, Jenabian MA, Péré H, Charpentier C, Matta M, Longo JDD, Grésenguet G, Djoba Siawaya JF, Bélec L
Escalating and sustained immunovirological dissociation among antiretroviral drug-experienced perinatally human immunodeficiency virus-1-infected children and adolescents living in the Central African Republic: A STROBE-compliant study.
Medicine 2020, 99, e19978.

Le Hingrat Q, Visseaux B, Bertine M, Chauveau L, Schwartz O, Collin F, Damond F, Matheron S, Descamps D, Charpentier C
Genetic Variability of Long Terminal Repeat Region between HIV-2 Groups Impacts Transcriptional Activity.
Journal of Virology 2020, 94,

Le Hingrat Q, Ghanem M, Cazes A, Visseaux B, Collin G, Descamps D, Charpentier C, Crestani B
No association between human herpesvirus or herpesvirus saimiri and idiopathic pulmonary fibrosis.
ERJ Open Research 2020, 6, 00243-2020.

Tchounga BK, Charpentier C, Coffie PA, Dabis F, Descamps D, Eholie SP, Ekouevi DK
Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa.
PloS One 2020, 15, e0236642.

Mboumba Bouassa RS, Pere H, Mossoro-Kpinde CD, Roques P, Gody JC, Moussa S, Veyer D, Gresenguet G, Charpentier C, Jenabian MA, Djoba Siawaya JF, Belec L
Purifying Selection in Human Immunodeficiency Virus-1 pol Gene in Perinatally Human Immunodeficiency Virus-1-Infected Children Harboring Discordant Immunological Response and Virological Nonresponse to Long-Term Antiretroviral Therapy.
Journal of Clinical Medicine Research 2020, 12, 369-376.

Iannetta M, Isnard S, Manuzak J, Guillerme JB, Notin M, Bailly K, Andrieu M, Amraoui S, Vimeux L, Figueiredo S, Charmeteau-de Muylder B, Vaton L, Hatton EX, Samri A, Autran B, Thiébaut R, Chaghil N, Glohi D, Charpentier C, Descamps D, Brun-Vézinet F, Matheron S, Cheynier R, Hosmalin A
Conventional Dendritic Cells and Slan+ Monocytes During HIV-2 Infection.
Frontiers in Immunology 2020, 11, 1658.

Mihimit A, Adawaye C, Péré H, Costiniuk C, Koyalta D, Mbopi-Keou FX, Bouassa RSM, Talla F, Moussa S, Longo JDD, Tchombou BHZ, Grésenguet G, Charpentier C, Bélec L
HSV-2 Infection as a Potential Cofactor for HIV Disease Progression and Selection of Drug Resistance Mutations in Adults under WHO-Recommended First-Line Antiretroviral Therapy: A Multicentric, Cross-Sectional Study in Cameroon, Central African Republic, Chad, and Gabon.
Tropical Medicine and Infectious Disease 2020, 5, 136.

2019


Brunet-Possenti F, Charpentier C, Bouhnik Y, Deschamps L, Descamps D, Moins-Teisserenc H, Descamps V
Occurrence of Extensive Cutaneous Human Papillomavirus Infection After Initiation of Tofacitinib Therapy.
JAMA Dermatology 2019, 155, 629.

Miailhe AF, Mercier E, Maamar A, Lacherade JC, Le Thuaut A, Gaultier A, Asfar P, Argaud L, Ausseur A, Ben Salah A, Botoc V, Chaoui K, Charpentier J, Cracco C, De Prost N, Eustache ML, Ferré A, Gauvin E, Goursaud S, Grall M, Guiot P, Jonas M, Lambiotte F, Landais M, Lemarié J, Lesieur O, Lhommet C, Michel P, Monseau Y, Moschietto S, Nseir S, Osman D, Pillot J, Piton G, Sedillot N, Sirodot M, Thevenin D, Zafrani L, Zerbib Y, Bourhy P, Lascarrou JB, Reignier J, L
Severe leptospirosis in non-tropical areas: a nationwide, multicentre, retrospective study in French ICUs.
Intensive Care Medicine 2019, 45, 1763-1773.

Ferré V, Ekouevi D, Gbeasor-Komlanvi F, Collin G, Le Hingrat Q, Tchounga B, Salou M, Descamps D, Charpentier C, Dagnra A
Prevalence of human papillomavirus, human immunodeficiency virus and other sexually transmitted infections among female sex workers in Togo: a national cross-sectional survey.
Clinical Microbiology and Infection 2019, 25, 1560.e1-1560.e7.

Le Hingrat Q, Perrier M, Charpentier C, Jacquot A, Houhou-Fidouh N, Descamps D, Visseaux B
Was Zika introduced to Brazil by participants at the 2013 Beach Soccer World Cup held in Tahiti: A phylogeographical analysis.
Travel Medicine and Infectious Disease 2019, 101512.

Le Hingrat Q, Charpentier C, Ghosn J, Thiébaut R, Peytavin G, Descamps D, Matheron S
New insights are game-changers in HIV-2 disease management.
The lancet. HIV 2019, 6, e214.

Parisey M, Louni F, Bouvet E, Landman R, Charpentier C, Lariven S, Joly V, Villemant A, Mackoumbou-Nkouka C, Yazdanpanah Y, Burdet C
HIV Infection in North African Patients.
AIDS research and human retroviruses 2019, 35, 628-633.

Bonnet B, Blum L, Charpentier C, Martres P, Ritvo PG, Autran B, Guihot A
Short Communication: Extremely Severe CD4 Lymphopenia During HIV-1 Primary Infection.
AIDS Research and Human Retroviruses 2019, 35, 930-933.

Ferré VM, Gbeasor-Komlanvi FA, Collin G, Dagnra AC, Le Hingrat Q, Jaquet A, Salou M, Descamps D, Charpentier C, Ekouevi DK
Prevalence of Human Papillomavirus, Human Immunodeficiency Virus, and Other Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo: A National Cross-sectional Survey.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2019, 69, 1019-1026.

Le Hingrat Q, Collin G, Lê M, Peytavin G, Visseaux B, Bertine M, Tubiana R, Karmochkine M, Valin N, Collin F, Lemaignen A, Bernard L, Damond F, Matheron S, Descamps D, Charpentier C, FNAfRoAaVH(CH2C
A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2019, 69, 657-667.

Soulie C, Santoro MM, Charpentier C, Storto A, Paraskevis D, Di Carlo D, Gennari W, Sterrantino G, Zazzi M, Perno CF, Calvez V, Descamps D, Ceccherini-Silberstein F, Marcelin AG
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.
The Journal of Antimicrobial Chemotherapy 2019, 74, 614-617.

Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, Cabié A, Benalycherif A, Peytavin G, Yeni P, Mentre F, Argoud AL, Amri I, Descamps D, Yazdanpanah Y, LSG
Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).
The Journal of Antimicrobial Chemotherapy 2019, 74, 739-745.

Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M, Trabaud MA, Le Guillou-Guillemette H, Allaoui C, Henquell C, Krivine A, Dos Santos G, Delamare C, Bouvier-Alias M, Montes B, Ferre V, De Monte A, Signori-Schmuck A, Maillard A, Morand-Joubert L, Tumiotto C, Fafi-Kremer S, Amiel C, Barin F, Marque-Juillet S, Courdavault L, Vallet S, Beby-Defaux A, de Rougemont A, Fenaux H, Avettand-Fenoel V, Allardet-Servent A, Plantier JC, Peytavin G, Calvez V, Chaix ML, Descamps D, AA4RSG
Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1417-1424.

Marcelin AG, Grude M, Charpentier C, Bellecave P, Le Guen L, Pallier C, Raymond S, Mirand A, Bocket L, Fofana DB, Delaugerre C, Nguyen T, Montès B, Jeulin H, Mourez T, Fafi-Kremer S, Amiel C, Roussel C, Dina J, Trabaud MA, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Maillard A, Ferre V, Descamps D, Calvez V, Flandre P, AARG
Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1368-1375.

Perrier M, Castain L, Regad L, Todesco E, Landman R, Visseaux B, Yazdanpanah Y, Rodriguez C, Joly V, Calvez V, Marcelin AG, Descamps D, Charpentier C
HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1679-1692.

Mboumba Bouassa RS, Mossoro-Kpinde CD, Gody JC, Veyer D, Péré H, Matta M, Robin L, Grésenguet G, Charpentier C, Bélec L
High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO.
Journal of Antimicrobial Chemotherapy 2019, 74, 2030-2038.

Castain L, Perrier M, Charpentier C, Palich R, Desire N, Wirden M, Descamps D, Sayon S, Landman R, Valantin MA, Joly V, Peytavin G, Yazdanpanah Y, Katlama C, Calvez V, Marcelin AG, Todesco E
New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
The Journal of Antimicrobial Chemotherapy 2019, 74, 2019-2023.

Bourcier S, Coutrot M, Kimmoun A, Sonneville R, de Montmollin E, Persichini R, Schnell D, Charpentier J, Aubron C, Morawiec E, Bigé N, Nseir S, Terzi N, Razazi K, Azoulay E, Ferré A, Tandjaoui-Lambiotte Y, Ellrodt O, Hraiech S, Delmas C, Barbier F, Lautrette A, Aissaoui N, Repessé X, Pichereau C, Zerbib Y, Lascarrou JB, Carreira S, Reuter D, Frérou A, Peigne V, Fillatre P, Megarbane B, Voiriot G, Combes A, Schmidt M
Thyroid Storm in the ICU: A Retrospective Multicenter Study.
Critical Care Medicine 2019

Samri A, Charpentier C, Diallo MS, Bertine M, Even S, Morin V, Oudin A, Parizot C, Collin G, Hosmalin A, Cheynier R, Thiébaut R, Matheron S, Collin F, Zoorob R, Brun-Vézinet F, Autran B, ACI2SG
Limited HIV-2 reservoirs in central-memory CD4 T-cells associated to CXCR6 co-receptor expression in attenuated HIV-2 infection.
PLoS pathogens 2019, 15, e1007758.

Visseaux B, Le Hingrat Q, Damond F, Charpentier C, Descamps D
[Physiopathology of HIV-2 infection].
Virologie (Montrouge, France) 2019, 23, 277-291.

Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, Günthard HF, Paredes R, Shafer RW, Richman DD
2019 update of the drug resistance mutations in HIV-1.
Topics in Antiviral Medicine 2019, 27, 111-121.

2018


Brunet-Possenti F, Deschamps L, Charpentier C
Use of Combination Systemic-Intratumoral HPV Vaccine to Treat Cutaneous Basaloid Squamous Cell Carcinomas.
JAMA dermatology 2018

Soulie C, Morand-Joubert L, Cottalorda J, Charpentier C, Bellecave P, Le Guen L, Yerly S, Montes B, Fafi-Kremer S, Dina J, Avettand-Fenoel V, Amiel C, Roussel C, Pallier C, Zafilaza K, Sayon S, Signori-Schmuck A, Mirand A, Trabaud MA, Berger S, Calvez V, Marcelin AG, AArg
Performance of genotypic algorithms for predicting tropism for HIV-1 CRF01_AE recombinant.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2018, 99-100, 57-60.

Le Hingrat Q, Perrier M, Collin G, Drumard S, Storto A, Bertine M, Larrouy L, Matheron S, Damond F, Charpentier C, Descamps D, Visseaux B
Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads.
Journal of Virological Methods 2018, 257, 12-15.

Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, Timsit JF, Misset B, Ali Benali M, Colin G, Souweine B, Asehnoune K, Mercier E, Chimot L, Charpentier C, François B, Boulain T, Petitpas F, Constantin JM, Dhonneur G, Baudin F, Combes A, Bohé J, Loriferne JF, Amathieu R, Cook F, Slama M, Leroy O, Capellier G, Dargent A, Hissem T, Maxime V, Bellissant E, CTN
Hydrocortisone plus Fludrocortisone for Adults with Septic Shock.
The New England Journal of Medicine 2018, 378, 809-818.

Matheron S, Descamps D, Gallien S, Besseghir A, Sellier P, Blum L, Mortier E, Charpentier C, Tubiana R, Damond F, Peytavin G, Ponscarme D, Collin F, Brun-Vezinet F, Chene G, A1H2tSG
First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2).
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2018

Mariaggi AA, Péré H, Perrier M, Visseaux B, Collin G, Veyer D, Hingrat QL, Ferré VM, Joly V, Couvelard A, Bucau M, Davitian C, Descamps D, Abramowitz L, Charpentier C
Presence of HPV APOBEC-related Minority Variants in HPV16 Genomes from Anal and Cervical Samples but not in HPV52 and HPV58.
The Journal of Infectious Diseases 2018

Perrier M, Visseaux B, Landman R, Joly V, Todesco E, Yazdanpanah Y, Calvez V, Marcelin AG, Descamps D, Charpentier C
No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
The Journal of Antimicrobial Chemotherapy 2018, 73, 173-176.

Charpentier C, Malet I, Andre-Garnier E, Storto A, Bocket L, Amiel C, Morand-Joubert L, Tumiotto C, Nguyen T, Maillard A, Rodallec A, Leoz M, Montes B, Schneider V, Plantier JC, Dina J, Pallier C, Mirand A, Roussel C, Signori-Schmuck A, Raymond S, Calvez V, Delaugerre C, Marcelin AG, Descamps D
Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.
The Journal of Antimicrobial Chemotherapy 2018

Storto A, Visseaux B, Bertine M, Le Hingrat Q, Collin G, Damond F, Khuong MA, Blum L, Tubiana R, Karmochkine M, Cazanave C, Matheron S, Descamps D, Charpentier C, AH2CC
Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients.
The Journal of Antimicrobial Chemotherapy 2018

Charpentier C, Peytavin G, Lê MP, Joly V, Cabras O, Perrier M, Le Gac S, Phung B, Yazdanpanah Y, Descamps D, Landman R
High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort.
The Journal of Antimicrobial Chemotherapy 2018, 73, 1665-1671.

Lambert-Niclot S, Grude M, Chaix ML, Charpentier C, Reigadas S, Le Guillou-Guillemette H, Rodallec A, Amiel C, Maillard A, Dufayard J, Mourez T, Mirand A, Guinard J, Montes B, Vallet S, Marcelin AG, Descamps D, Flandre P, Delaugerre C, Morand-Joubert L, AA1RG
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
The Journal of Antimicrobial Chemotherapy 2018

Nguyen T, Fofana DB, Lê MP, Charpentier C, Peytavin G, Wirden M, Lambert-Niclot S, Desire N, Grude M, Morand-Joubert L, Flandre P, Katlama C, Descamps D, Calvez V, Todesco E, Marcelin AG
Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing.
The Journal of Antimicrobial Chemotherapy 2018, 73, 2485-2492.

Alessandri-Gradt E, Charpentier C, Leoz M, Mourez T, Descamps D, Plantier JC
Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir.
The Journal of Antimicrobial Chemotherapy 2018

Cazals N, Le Hingrat Q, Abraham B, Da Silva P, Guindre L, Goffart S, Damond F, Visseaux B, Charpentier C, Ranger-Rogez S, Descamps D
HIV-2 Primary Infection in a French 69-Year-Old Bisexual Man.
Open Forum Infectious Diseases 2018, 5, ofy223.

Brunet-Possenti F, Charpentier C, Collin G, Descamps D, Descamps V
Impact of anti-interleukin-17 treatment on cutaneous and genital human papillomavirus infection.
The British Journal of Dermatology 2018, 179, 1179-1180.

Pouga L, Mercedes Santoro M, Charpentier C, Di Carlo D, Romeo I, Artese A, Alcaro S, Antinori A, Wirden M, Perno CF, Ambrosio FA, Calvez V, Descamps D, Marcelin AG, Ceccherini-Silberstein F, Lambert-Niclot S
New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T).
Chemical Biology & Drug Design 2018

Nassereddine H, Charpentier C, Bucau M, Joly V, Bienvenu L, Davitian C, Abramowitz L, Benabderrahmane D, Kotelevets L, Chastre E, Lehy T, Walker F
Interest of cytology combined with Xpert® HPV and Anyplex® II HPV28 Detection human papillomavirus (HPV) typing: differential profiles of anal and cervical HPV lesions in HIV-infected patients on antiretroviral therapy.
HIV medicine 2018

Perrier M, Désiré N, Storto A, Todesco E, Rodriguez C, Bertine M, Le Hingrat Q, Visseaux B, Calvez V, Descamps D, Marcelin AG, Charpentier C
Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants.
PloS One 2018, 13, e0198334.

Ségéral O, Nerrienet E, Neth S, Spire B, Khol V, Ferradini L, Sarun S, Mom C, Ngin S, Charpentier C, Men P, Mora M, Mean Chhi V, Ly P, Saphonn V
Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study.
Frontiers in Public Health 2018, 6, 63.

Charpentier C, Descamps D
Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.
Viruses 2018, 10,

2017


Rhee SY, Varghese V, Holmes SP, Van Zyl GU, Steegen K, Boyd MA, Cooper DA, Nsanzimana S, Saravanan S, Charpentier C, de Oliveira T, Etiebet MAA, Garcia F, Goedhals D, Gomes P, Günthard HF, Hamers RL, Hoffmann CJ, Hunt G, Jiamsakul A, Kaleebu P, Kanki P, Kantor R, Kerschberger B, Marconi VC, D'amour Ndahimana J, Ndembi N, Ngo-Giang-Huong N, Rokx C, Santoro MM, Schapiro JM, Schmidt D, Seu L, Sigaloff KCE, Sirivichayakul S, Skhosana L, Sunpath H, Tang M, Yang C, Carmona S, Gupta RK, Shafer RW
Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: An international collaboration.
EBioMedicine 2017

Wirden M, Larrouy L, Mahjoub N, Todesco E, Damond F, Delagreverie H, Akhavan S, Charpentier C, Chaix ML, Descamps D, Calvez V, Marcelin AG
Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2017, 96, 49-53.

Asfar P, Schortgen F, Boisramé-Helms J, Charpentier J, Guérot E, Megarbane B, Grimaldi D, Grelon F, Anguel N, Lasocki S, Henry-Lagarrigue M, Gonzalez F, Legay F, Guitton C, Schenck M, Doise JM, Devaquet J, Van Der Linden T, Chatellier D, Rigaud JP, Dellamonica J, Tamion F, Meziani F, Mercat A, Dreyfuss D, Seegers V, Radermacher P, HI, Rrn
Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial.
The Lancet. Respiratory Medicine 2017, 5, 180-190.

Senard O, Burdet C, Visseaux B, Charpentier C, Le Gac S, Julia Z, Lariven S, Descamps D, Yazdanpanah Y, Yeni P, Joly V
Epidemiological Profile of Newly Diagnosed HIV-Infected Patients in Northern Paris: A Retrospective Study.
AIDS Res Hum Retroviruses 2017, 33, 11-16.

Raymond S, Nicot F, Pallier C, Bellecave P, Maillard A, Trabaud MA, Morand-Joubert L, Rodallec A, Amiel C, Mourez T, Bocket L, Beby-Defaux A, Bouvier-Alias M, Lambert-Niclot S, Charpentier C, Malve B, Mirand A, Dina J, Le Guillou-Guillemette H, Marque-Juillet S, Signori-Schmuck A, Barin F, Si-Mohamed A, Avettand Fenoel V, Roussel C, Calvez V, Saune K, Marcelin AG, Rodriguez C, Descamps D, Izopet J, AARSG
Impact of HIV-1 minority variants on the virus response to a rilpivirine-based first line regimen.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2017

Unal G, Alessandri-Gradt E, Leoz M, Pavie J, Lefevre C, Panjo H, Charpentier C, Descamps D, Barin F, Simon F, Meyer L, Plantier JC
HIV-1 group O infection in France: clinical features and immunovirological response to antiretrovirals.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2017

Wirden M, Charpentier C, Tubiana R, Le MP, Desire N, Dionou S, Pichon F, Valantin MA, Yasdanpanah Y, Descamps D, Peytavin G, Katlama C, Calvez V, Marcelin AG
HIV-1 diagnosis with unquantifiable viraemia: don't be naive, look for antiretroviral drugs.
The Journal of Antimicrobial Chemotherapy 2017, 72, 630-632.

Madelain V, Le MP, Champenois K, Charpentier C, Landman R, Joly V, Yeni P, Descamps D, Yazdanpanah Y, Peytavin G
Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.
The Journal of Antimicrobial Chemotherapy 2017, 72, 1137-1146.

Perrier M, Charpentier C, Peytavin G, Lê M, Blondel L, Visseaux B, Joly V, Pinto A, Matheron S, Yazdanpanah Y, Descamps D, Landman R
Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
The Journal of Antimicrobial Chemotherapy 2017, 72, 1745-1751.

Assoumou L, Charpentier C, Recordon-Pinson P, Grudé M, Pallier C, Morand-Joubert L, Fafi-Kremer S, Krivine A, Montes B, Ferré V, Bouvier-Alias M, Plantier JC, Izopet J, Trabaud MA, Yerly S, Dufayard J, Alloui C, Courdavault L, Le Guillou-Guillemette H, Maillard A, Amiel C, Vabret A, Roussel C, Vallet S, Guinard J, Mirand A, Beby-Defaux A, Barin F, Allardet-Servent A, Ait-Namane R, Wirden M, Delaugerre C, Calvez V, Chaix ML, Descamps D, Reigadas S, AA1RSG
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study.
The Journal of Antimicrobial Chemotherapy 2017, 72, 1769-1773.

Alessandri-Gradt E, Collin G, Tourneroche A, Bertine M, Leoz M, Charpentier C, Unal G, Descamps D, Plantier JC
HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.
The Journal of Antimicrobial Chemotherapy 2017, 72, 2431-2437.

Perrier M, Bertine M, Le Hingrat Q, Joly V, Visseaux B, Collin G, Landman R, Yazdanpanah Y, Descamps D, Charpentier C
Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients.
The Journal of Antimicrobial Chemotherapy 2017, 72, 2954-2955.

Charpentier C, Montes B, Perrier M, Meftah N, Reynes J
HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study.
The Journal of Antimicrobial Chemotherapy 2017, 72, 2831-2836.

Papot E, Landman R, Louni F, Charpentier C, Peytavin G, Certain A, Fradet C, Castro DR, Preau M, Goujard C, Yeni P, Yazdanpanah Y, AGSG
Budget impact of antiretroviral therapy in a French clinic cohort.
AIDS (London, England) 2017, 31, 1271-1279.

Todesco E, Charpentier C, Bertine M, Wirden M, Storto A, Desire N, Grude M, Nguyen T, Sayon S, Yazdanpanah Y, Katlama C, Descamps D, Calvez V, Marcelin AG
Disparities in HIV-1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations.
HIV medicine 2017, 18, 696-700.

Malet I, Subra F, Charpentier C, Collin G, Descamps D, Calvez V, Marcelin AG, Delelis O
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
mBio 2017

Douine M, Mosnier E, Le Hingrat Q, Charpentier C, Corlin F, Hureau L, Adenis A, Lazrek Y, Niemetsky F, Aucouturier AL, Demar M, Musset L, Nacher M
Illegal gold miners in French Guiana: a neglected population with poor health.
BMC public health 2017, 18, 23.

Carbonne H, Le Dorze M, Bourrel AS, Poupet H, Poyart C, Cambau E, Mira JP, Charpentier J, Amarsy R
Relation between presence of extended-spectrum β-lactamase-producing Enterobacteriaceae in systematic rectal swabs and respiratory tract specimens in ICU patients.
Annals of Intensive Care 2017, 7, 13.

Visseaux B, Collin G, Ichou H, Charpentier C, Bendhafer S, Dumitrescu M, Allal L, Cojocaru B, Desfrère L, Descamps D, Mandelbrot L, Houhou-Fidouh N
Usefulness of multiplex PCR methods and respiratory viruses' distribution in children below 15 years old according to age, seasons and clinical units in France: A 3 years retrospective study.
PloS One 2017, 12, e0172809.

Visseaux B, Burdet C, Voiriot G, Lescure FX, Chougar T, Brugiere O, Crestani B, Casalino E, Charpentier C, Descamps D, Timsit JF, Yazdanpanah Y, Houhou-Fidouh N
Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016.
PLoS One 2017, 12, e0180888.

Delory T, Ferrand H, Grall N, Casalino E, Lafarge M, Melot B, Hajage D, Charpentier C, Aubier M, Tubach F, Bouvet E, Gault N, Yazdanpanah Y
Score for pulmonary tuberculosis in patients with clinical presumption of tuberculosis in a low-prevalence area.
Int J Tuberc Lung Dis 2017, 21, 1272-1279.

2016


Delory T, Papot E, Rioux C, Charpentier C, Auge-Courtoi C, Michard F, Peytavin G, Descamps D, Matheron S, Yazdanpanah Y
Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.
Journal of Medical Virology 2016, 88, 1204-1210.

Visseaux B, Damond F, Matheron S, Descamps D, Charpentier C
Hiv-2 molecular epidemiology.
Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 2016, 46, 233-240.

Benmoussa N, Charpentier C, Mariaggi AA, Collin G, Descamps D, Hourseau M, Barry B, Albert S, Picard A, Conan P, Charlier P
HPV 16 in squamous cell carcinoma of 19th century tonsils.
The Lancet. Oncology 2016, 17, e477–e478.

Visseaux B, Mortier E, Houhou-Fidouh N, Brichler S, Collin G, Larrouy L, Charpentier C, Descamps D
Zika virus in the female genital tract.
The Lancet. Infectious Diseases 2016, 16, 1220.

Bocket L, Peytavin G, Alidjinou EK, Ajana F, Choisy P, Lê M, Charpentier C, Descamps D, Yazdanpanah Y, Katlama C, Simon A, Calvez V, Marcelin AG, Soulie C
Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
The Journal of Antimicrobial Chemotherapy 2016, 71, 2651-2653.

Bertine M, Visseaux B, Storto A, Collin G, Matheron S, Descamps D, Charpentier C, ACH2C
HIV-2 Vif Diversity Among Defective and Nondefective Sequences.
Journal of Acquired Immune Deficiency Syndromes (1999) 2016, 72, e9–e11.

2015


LeGoff J, Roques P, Jenabian MA, Charpentier C, Brochier C, Bouhlal H, Gresenguet G, Frost E, Pepin J, Mayaud P, Belec L, A1SG
Variability of human immunodeficiency virus-1 in the female genital reservoir during genital reactivation of herpes simplex virus type 2.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2015, 21, 873.e1-9.

Soulie C, Peytavin G, Charpentier C, Lambert-Niclot S, Sayon S, Visseaux B, Simon A, Katlama C, Yazdanpanah Y, Descamps D, Calvez V, Marcelin AG
Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.
AIDS research and human retroviruses 2015, 31, 475-478.

Descamps D, Peytavin G, Visseaux B, Tubiana R, Damond F, Campa P, Charpentier C, Khuong-Josses MA, Duvivier C, Karmochkine M, Lukiana T, Matheron S
Dolutegravir in HIV-2 infected patients with resistant virus to first-line integrase inhibitors from the French Named Patient Program.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2015

Charpentier C, Camacho R, Ruelle J, Eberle J, Gürtler L, Pironti A, Stürmer M, Brun-Vézinet F, Kaiser R, Descamps D, Obermeier M
HIV-2EU-Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2015, 61, 1346–1347.

Fofana DB, Charpentier C, Maïga AI, Lambert-Niclot S, Sayon S, Désiré N, Simon A, Yazdanpanah Y, Katlama C, Descamps D, Calvez V, Marcelin AG, Soulié C
Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.
The Journal of Antimicrobial Chemotherapy 2015, 70, 130-135.

Lê MP, Landman R, Koulla-Shiro S, Charpentier C, Sow PS, Diallo MB, Ngom Gueye NF, Ngolle M, Le Moing V, Eymard-Duvernay S, Benalycherif A, Delaporte E, Girard PM, Peytavin G, DSG
Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1517–1521.

Fourati S, Charpentier C, Amiel C, Morand-Joubert L, Reigadas S, Trabaud MA, Delaugerre C, Nicot F, Rodallec A, Maillard A, Mirand A, Jeulin H, Montès B, Barin F, Bettinger D, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Descamps D, Calvez V, Flandre P, Marcelin AG, AARSG
Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1507–1512.

Loubet P, Charpentier C, Visseaux B, Borbor A, Nuta C, Adu E, Chapplain JM, Baysah M, Tattevin P, Yazdanpanah Y, Descamps D
Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1881-1884.

Charpentier C, Lee GQ, Rodriguez C, Visseaux B, Storto A, Fagard C, Molina JM, Katlama C, Yazdanpanah Y, Harrigan PR, Descamps D
Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
The Journal of Antimicrobial Chemotherapy 2015, 70, 2090-2096.

Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D, ACH2C
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
AIDS (London, England) 2015, 29, 779–784.

Péré H, Roques P, Talla F, Meillo H, Charpentier C, Bélec L
Sustained virological failure in Cameroonese patient infected by HIV-1 group N evidenced by sequence-based genotyping assay.
AIDS (London, England) 2015, 29, 1267–1269.

Cuzin L, Pugliese P, Sauné K, Allavena C, Ghosn J, Cottalorda J, Rodallec A, Chaix ML, Fafi-Kremer S, Soulié C, Ouka M, Charpentier C, Bocket L, Mirand A, Guiguet M, Dsg
Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy.
AIDS (London, England) 2015, 29, 1665–1671.

Visseaux B, Charpentier C, Ozanne A, Nizard A, Drumard S, Fagard C, Glohi D, Damond F, Brun-Vézinet F, Matheron S, Descamps D, ACH2C
Tropism distribution among antiretroviral-naive HIV-2-infected patients.
AIDS (London, England) 2015, 29, 2209–2212.

Pain JB, Lê MP, Caseris M, Amiel C, Lassel L, Charpentier C, Desnoyer A, Farnoux C, Pialoux G, Descamps D, Peytavin G
Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.
Antimicrobial Agents and Chemotherapy 2015, 59, 3660–3662.

Deuzing IP, Charpentier C, Wright DW, Matheron S, Paton J, Frentz D, van de Vijver DA, Coveney PV, Descamps D, ACH2C, Boucher CAB, Beerens N
Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.
J. Virol. 2015, 89, 833–843.

Rodriguez C, Soulié C, Marcelin AG, Calvez V, Descamps D, Charpentier C, Flandre P, Recordon-Pinson P, Bellecave P, Pawlotsky JM, Masquelier B, AASG
HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.
PloS One 2015, 10, e0127816.

Charpentier C, Lê MP, Joly V, Visseaux B, Lariven S, Phung B, Yéni P, Yazdanpanah Y, Descamps D, Peytavin G, Landman R
Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.
PloS One 2015, 10, e0134430.

Visseaux B, Charpentier C, Collin G, Bertine M, Peytavin G, Damond F, Matheron S, Lefebvre E, Brun-Vézinet F, Descamps D, ACH2C
Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
PloS One 2015, 10, e0134904.

Jenabian MA, Talla F, Talla P, Mbopi-Kéou FX, Charpentier C, Kane CT, Bélec L
Pitfalls of antiretroviral drug resistance genotyping of HIV-1 Group M and Group N from Cameroon by sequenced-based assays.
Nigerian Medical Journal: Journal of the Nigeria Medical Association 2015, 56, 420–424.

2014


Benenson JF, Kuhn MN, Ryan PJ, Ferranti AJ, Blondin R, Shea M, Charpentier C, Thompson ME, Wrangham RW
Human males appear more prepared than females to resolve conflicts with same-sex peers.
Human Nature (Hawthorne, N.Y.) 2014, 25, 251–268.

Loubet P, Charpentier C, Visseaux B, Nuta C, Adu E, Chapplain JM, Baysah M, Walters-Doe S, Tattevin P, Peytavin G, Yazdanpanah Y, Descamps D
Short communication: Prevalence of HIV-1 transmitted drug resistance in Liberia.
AIDS research and human retroviruses 2014, 30, 863-866.

Lambert-Niclot S, Charpentier C, Storto A, Fofana D, Soulie C, Fourati S, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
The Journal of Antimicrobial Chemotherapy 2014, 69, 1086–1089.

Charpentier C, Joly V, Ghosn J, Yeni P, Raffi F, Descamps D, Morand-Joubert L
Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen.
The Journal of Antimicrobial Chemotherapy 2014, 69, 2588–2590.

Charpentier C, Choquet M, Joly V, Yeni P, Visseaux B, Caseris M, Brun-Vézinet F, Yazdanpanah Y, Peytavin G, Descamps D, Landman R
Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.
The Journal of Antimicrobial Chemotherapy 2014, 69, 2819-2825.

Charpentier C, Eholié S, Anglaret X, Bertine M, Rouzioux C, Avettand-Fenoël V, Messou E, Minga A, Damond F, Plantier JC, Dabis F, Peytavin G, Brun-Vézinet F, Ekouevi DK, IWAC
Genotypic resistance profiles of HIV-2-treated patients in West Africa.
AIDS (London, England) 2014, 28, 1161–1169.

Visseaux B, Charpentier C, Rouard C, Fagard C, Glohi D, Tubiana R, Damond F, Brun-Vézinet F, Matheron S, Descamps D, FH2ACC
HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients.
AIDS (London, England) 2014, 28, 2160–2162.

Landman R, Koulla-Shiro S, Sow PS, Ngolle M, Diallo MB, Guèye NFN, Le Moing V, Eymard-Duvernay S, Benalycherif A, Charpentier C, Peytavin G, Delaporte E, Girard PM, DSG
Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.
Antiviral Therapy 2014, 19, 51–59.

Marcelin AG, Charpentier C, Wirden M, Descamps D, Calvez V
Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment.
Journal of the International AIDS Society 2014, 17, 19744.

2013


Kebe K, Thiam M, Diagne Gueye NR, Diop H, Dia A, Signate Sy H, Charpentier C, Belec L, Mboup S, Toure Kane C
High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines.
AIDS research and human retroviruses 2013, 29, 242-249.

Charpentier C, Camacho R, Ruelle J, Kaiser R, Eberle J, Gürtler L, Pironti A, Stürmer M, Brun-Vézinet F, Descamps D, Obermeier M
HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2013, 56, 1654-1658.

Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, Hamers RL, de Wit TFR, Fleury HJ, Kanki PJ, Ruxrungtham K, Hawkins CA, Wallis CL, Stevens W, van Zyl GU, Manosuthi W, Hosseinipour MC, Ngo-Giang-Huong N, Belec L, Peeters M, Aghokeng A, Bunupuradah T, Burda S, Cane P, Cappelli G, Charpentier C, Dagnra AY, Deshpande AK, El-Katib Z, Eshleman SH, Fokam J, Gody JC, Katzenstein D, Koyalta DD, Kumwenda JJ, Lallemant M, Lynen L, Marconi VC, Margot NA, Moussa S, Ndung'u T, Nyambi PN, Orrell C, Schapiro JM, Schuurman R, Sirivichayakul S, Smith D, Zolfo M, Jordan MR, Shafer RW
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
The Journal of Infectious Diseases 2013, 207 Suppl 2, S70-77.

Charpentier C, Joly V, Larrouy L, Fagard C, Visseaux B, de Verdière NC, Raffi F, Yeni P, Descamps D, A1ATSG
Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.
The Journal of Antimicrobial Chemotherapy 2013, 68, 690-696.

Lambert-Niclot S, Charpentier C, Storto A, Fofana DB, Soulié C, Fourati S, Visseaux B, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
The Journal of Antimicrobial Chemotherapy 2013, 68, 1237-1242.

Charpentier C, Lambert-Niclot S, Visseaux B, Morand-Joubert L, Storto A, Larrouy L, Landman R, Calvez V, Marcelin AG, Descamps D
Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010.
The Journal of Antimicrobial Chemotherapy 2013, 68, 2197-2198.

Fourati S, Visseaux B, Armenia D, Morand-Joubert L, Artese A, Charpentier C, Van Den Eede P, Costa G, Alcaro S, Wirden M, Perno CF, Ceccherini Silberstein F, Descamps D, Calvez V, Marcelin AG
Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors.
The Journal of Antimicrobial Chemotherapy 2013, 68, 2199-2204.

Descamps D, Assoumou L, Chaix ML, Chaillon A, Pakianather S, de Rougemont A, Storto A, Dos Santos G, Krivine A, Delaugerre C, Montes B, Izopet J, Charpentier C, Wirden M, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Guinard J, Tamalet C, Cottalorda J, Marcelin AG, Desbois D, Henquell C, Calvez V, Brun-Vézinet F, Masquelier B, Costagliola D, AARSG
National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.
The Journal of Antimicrobial Chemotherapy 2013, 68, 2626-2631.

Charpentier C, Bertine M, Visseaux B, Leleu J, Larrouy L, Peytavin G, Mourez T, Collin G, Brun-Vézinet F, Plantier JC, Descamps D
In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.
AIDS (London, England) 2013, 27, 2959-2961.

Larrouy L, Vivot A, Charpentier C, Bénard A, Visseaux B, Damond F, Matheron S, Chene G, Brun-Vezinet F, Descamps D, ACH2C
Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
AIDS (London, England) 2013, 27, 69-80.

Visseaux B, Charpentier C, Taieb A, Damond F, Bénard A, Larrouy L, Chêne G, Brun-Vézinet F, Matheron S, Descamps D, ACH2C
Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA.
AIDS (London, England) 2013, 27, 292-295.

Charpentier C, Visseaux B, Bénard A, Peytavin G, Damond F, Roy C, Taieb A, Chêne G, Matheron S, Brun-Vézinet F, Descamps D, ACH2C
Transmitted drug resistance in French HIV-2-infected patients.
AIDS 2013, 27, 1671–1674.

Leoz M, Feyertag F, Charpentier C, Delaugerre C, Wirden M, Lemee V, Plantier JC
Characterization of CRF56_cpx, a new circulating B/CRF02/G recombinant form identified in MSM in France.
AIDS (London, England) 2013, 27, 2309-2312.

Nguyen HL, Charpentier C, Nguyen N, de Truchis P, Molina JM, Ruxrungtham K, Delaugerre C
Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.
HIV medicine 2013, 14, 85-91.

Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P, S1ATG
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Antimicrobial Agents and Chemotherapy 2013, 57, 758-765.

Annane D, Timsit JF, Megarbane B, Martin C, Misset B, Mourvillier B, Siami S, Chagnon JL, Constantin JM, Petitpas F, Souweine B, Amathieu R, Forceville X, Charpentier C, Tesnière A, Chastre J, Bohe J, Colin G, Cariou A, Renault A, Brun-Buisson C, Bellissant E, ATI
Recombinant human activated protein C for adults with septic shock: a randomized controlled trial.
American Journal of Respiratory and Critical Care Medicine 2013, 187, 1091-1097.

Charpentier C, Fagard C, Colin C, Katlama C, Molina JM, Jacomet C, Visseaux B, Taburet AM, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D, ATTsg
Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
PloS One 2013, 8, e53621.

Charpentier C, Lambert-Niclot S, Alteri C, Storto A, Flandre P, Svicher V, Perno CF, Brun-Vézinet F, Calvez V, Marcelin AG, Ceccherini-Silberstein F, Descamps D
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes.
PloS One 2013

Charpentier C, Champenois K, Gervais A, Landman R, Joly V, Le Gac S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, Yazdanpanah Y
Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients.
PloS One 2013, 8, e59205.

2012


Soulié C, Charpentier C, Flandre P, Nino C, Carcelain G, Simon A, Katlama C, Landman R, Brun-Vézinet F, Descamps D, Calvez V, Marcelin AG
Natural evolution of CD4+ cell count in patients with CD4 >350 or >500  cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism.
Journal of Medical Virology 2012, 84, 1853-1856.

Charpentier C, Piketty C, Laureillard D, Tisserand P, Si-Mohamed A, Weiss L, Bélec L
Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy.
European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 2012, 31, 129-133.

Mekinian A, Stirnemann J, Belmatoug N, Heraoui D, Fantin B, Fain O, Charpentier A, Rose C
Ferritinemia during type 1 Gaucher disease: mechanisms and progression under treatment.
Blood Cells, Molecules & Diseases 2012, 49, 53-57.

Péré H, Charpentier C, Mbelesso P, Dandy M, Matta M, Moussa S, De Dieu Longo J, Grésenguet G, Abraham B, Bélec L
Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
AIDS research and human retroviruses 2012, 28, 315-323.

Thiébaut R, Charpentier C, Damond F, Taieb A, Antoine R, Capeau J, Chêne G, Collin G, Matheron S, Descamps D, Brun-Vézinet F, FAH2CC
Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2012, 55, 1417-1425.

Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, AC0H2C
Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.
The Journal of Infectious Diseases 2012, 205, 111-120.

Marcelin AG, Charpentier C, Wirden M, Landman R, Valantin MA, Simon A, Katlama C, Yeni P, Descamps D, Aubron-Olivier C, Calvez V
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
The Journal of Antimicrobial Chemotherapy 2012, 67, 1475-1478.

Charpentier C, Larrouy L, Visseaux B, Landman R, Levittas M, Storto A, Damond F, Yazdanpanah Y, Yeni P, Brun-Vézinet F, Descamps D
Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
The Journal of Antimicrobial Chemotherapy 2012, 67, 1459-1461.

Charpentier C, Landman R, Laouénan C, Joly V, Hamet G, Damond F, Brun-Vézinet F, Mentré F, Descamps D, Yeni P
Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome.
The Journal of Antimicrobial Chemotherapy 2012, 67, 2231-2235.

Lambert-Niclot S, Masquelier B, Cohen Codar I, Soulie C, Delaugerre C, Morand-Joubert L, Charpentier C, Ferre V, Plantier JC, Montes B, Carret S, Perrot V, Peytavin G, Costagliola D, Calvez V, Marcelin AG, ESG
Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.
The Journal of Antimicrobial Chemotherapy 2012, 67, 2487-2493.

Fagard C, Colin C, Charpentier C, Rami A, Jacomet C, Yeni P, Vittecoq D, Katlama C, Molina JM, Descamps D, Chêne G, Yazdanpanah Y, A1TTG
Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.
Journal of Acquired Immune Deficiency Syndromes (1999) 2012, 59, 489-493.

Touchon M, Charpentier S, Pognard D, Picard B, Arlet G, Rocha EPC, Denamur E, Branger C
Antibiotic resistance plasmids spread among natural isolates of Escherichia coli in spite of CRISPR elements.
Microbiology (Reading, England) 2012, 158, 2997-3004.

Visseaux B, Charpentier C, Hurtado-Nedelec M, Storto A, Antoine R, Peytavin G, Damond F, Matheron S, Brun-Vézinet F, Descamps D, FAH2C(C0V2
In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
Antimicrobial Agents and Chemotherapy 2012, 56, 137-139.

Legriel S, Schraub O, Azoulay E, Hantson P, Magalhaes E, Coquet I, Bretonniere C, Gilhodes O, Anguel N, Megarbane B, Benayoun L, Schnell D, Plantefeve G, Charpentier J, Argaud L, Mourvillier B, Galbois A, Chalumeau-Lemoine L, Rivoal M, Durand F, Geffroy A, Simon M, Stoclin A, Pallot JL, Arbelot C, Nyunga M, Lesieur O, Troché G, Bruneel F, Cordoliani YS, Bedos JP, Pico F, CIPRESSG(
Determinants of recovery from severe posterior reversible encephalopathy syndrome.
PloS One 2012, 7, e44534.

2011


Depatureaux A, Charpentier C, Leoz M, Unal G, Damond F, Kfutwah A, Vessière A, Simon F, Plantier JC
Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M.
Journal of Acquired Immune Deficiency Syndromes (1999) 2011, 56, 139-145.

Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, Karmochkine M, Duval X, Chêne G, Storto A, Collin G, Bénard A, Damond F, Mouscadet JF, Brun-Vézinet F, Descamps D, FAH2C(C0V2
Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.
Antimicrobial Agents and Chemotherapy 2011, 55, 1293-1295.

Ni XJ, Delelis O, Charpentier C, Storto A, Collin G, Damond F, Descamps D, Mouscadet JF
G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
Retrovirology 2011, 8, 68.

Charpentier C, Larrouy L, Matheron S, Damond F, Delelis O, Mouscadet JF, Campa P, Chêne G, Brun-Vézinet F, Descamps D, FAH2C(C0
Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
Antiviral Therapy 2011, 16, 937-940.

2010


Stegmann S, Manea ME, Charpentier C, Damond F, Karmochkine M, Laureillard D, Si-Mohamed A, Weiss L, Piketty C
Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2010, 47, 79-81.

Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, Chêne G, Nie T, Schinazi R, Brun-Vézinet F, Descamps D, FAH2C(C0V2
In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.
AIDS (London, England) 2010, 24, 2753-2755.

Depatureaux A, Charpentier C, Collin G, Leoz M, Descamps D, Vessière A, Damond F, Rousset D, Brun-Vézinet F, Plantier JC
Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.
Antimicrobial Agents and Chemotherapy 2010, 54, 4016-4019.

2002


Mandelbrot L, Msellati P, Meda N, Leroy V, Likikouët R, Van de Perre P, Dequae-Merchadoux L, Sylla-Koko F, Ouangre A, Ouassa T, Ramon R, Gautier-Charpentier L, Cartoux M, Dosso M, Dabis F, Welffens-Ekra C, A0DSG
15 Month follow up of African children following vaginal cleansing with benzalkonium chloride of their HIV infected mothers during late pregnancy and delivery.
Sexually Transmitted Infections 2002, 78, 267-270.

1999


Msellati P, Meda N, Leroy V, Likikouët R, Van de Perre P, Cartoux M, Bonard D, Ouangre A, Combe P, Gautier-Charpentier L, Sylla-Koko F, Lassalle R, Dosso M, Welffens-Ekra C, Dabis F, Mandelbrot L
Safety and acceptability of vaginal disinfection with benzalkonium chloride in HIV infected pregnant women in west Africa: ANRS 049b phase II randomized, double blinded placebo controlled trial. DITRAME Study Group.
Sexually Transmitted Infections 1999, 75, 420-425.

1992


Rouby JJ, Martin De Lassale E, Poete P, Nicolas MH, Bodin L, Jarlier V, Le Charpentier Y, Grosset J, Viars P
Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects.
The American Review of Respiratory Disease 1992, 146, 1059-1066.